Boehringer Ingelheim has initiated GioTag, a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive (M+) advanced non-small cell lung cancer (NSCLC). Data from approximately 190 patients who received tyrosine kinase inhibitors (TKI) – afatinib* in first-line, followed by second-line osimertinib**as part of standard clinical practice – will be analysed to determine total time on treatment.
US regulators have accepted an application by AstraZeneca and MedImmune to expand the scope of Imfinzi (durvalumab) to include patients with a certain form of lung cancer.
Pfizer Inc. today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC), including those who were heavily pretreated.
The U.S. Food and Drug Administration (FDA) has granted Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT)'s Orphan Drug Designation to CK-101 (also known as RX518), the Company’s third-generation epidermal growth-factor receptor (EGFR) inhibitor, for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).
Johns Hopkins Medicine scientists have revealed a molecular pathway that lures cells down a path of genome duplication, a hallmark of cancer cells, which could potentially lead to new therapies and could stop the growth of cancers. Published in Science, the study reveals the consequences of molecules and enzymes triggering and regulating the process of making new cells out of the cells’ genetic material. Cells follow an orderly routine that begins with making a copy of their entire genome, followed by separating the genome copies and dividing the replicated DNA evenly into two “daughter” cells. When doing so, cells that are stressed can mistakenly run the risk of copying their genome again. Focusing on human cells that line breast ducts and lung tissue, scientists analysed thousands of images of single cells as they went through cell division and developed glowing biosensors to tag cyclin dependent kinases (CDKs), which play a ...
Researchers from the Francis Crick Institute, the National Cancer Institute of the US National Institutes of Health and Aalborg University in Denmark have revealed that vitamin D encourages the growth of a type of gut bacteria in mice, which provides better cancer immunity. The study published in Science found that vitamin D increases the amount of Bacteroides fragilis, providing better immunity to cancer in mice with transplanted tumours. Cancer, including female breast, lung, bowel and prostate cancers, was responsible for more than 18 million new cases worldwide in 2020, according to Cancer Research UK. After giving mice a diet rich in vitamin D, researchers discovered they had better immune resistance to experimentally transplanted cancers and improved responses to immunotherapy treatment. Furthermore, this effect was seen when gene editing was used to remove a protein that binds to vitamin D in the blood and keep it away from tissues. Researchers found ...
Bladder cancer, including papillary tumours, is the ninth most common cancer type worldwide Researchers from ETH Zurich and University Hospital Basel have revealed new insights for cancer research when focusing on mechanical changes in tumour tissue after investigating the early stages of bladder cancer. Researchers aimed to understand what governs the direction in which bladder tumours grow and whether it plays a role in malignant and benign formations. Currently the ninth most common cancer type worldwide, bladder cancer occurs when cells in the bladder start to grow without control. Papillary tumours, long, slender benign or malignant tumours that grow from tissue that lines the inside of the organ, are usually easy to treat, while muscle-invasive bladder cancer, which spreads into the thick muscle of the bladder wall, requires surgical removal of the bladder. Similar to bronchioles in the lungs, researchers wondered whether molecular mechanisms could be responsible for creating the ...
A new editorial paper was published in Oncoscience (Volume 11) on April 22, 2024, entitled, “Exploring oncogenic driver molecular alterations in Hispanic/Latin American cancer patients: A call for enhanced molecular understanding.” In this new editorial, researcher Rafael Parra-Medina from Fundación Universitaria de Ciencias de la Salud and Instituto Nacional de Cancerología begins by discussing Latin America’s (LA) population -; a heterogeneous mix of Amerindian, African, and Caucasian ancestries with different proportions in different regions. Countries such as Argentina, Brazil, Colombia, Costa Rica, Uruguay, and Venezuela have a higher proportion of Caucasian while regions in Mexico, Perú, and Bolivia have a higher proportion of Amerindian ancestries. Although the overall incidence of cancer in Latin American countries is generally lower compared to high-income nations, the mortality rate is notably higher. “This disparity can be attributed to several factors, including smoking habits, diet quality, levels of physical activity, access to healthcare services, and ...
ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The novel immunotherapy works by sparking activity from three types of immune cells. By Frank Vinluan Immunotherapy is already a treatment option for bladder cancer, but in many cases, these therapies fail or the cancer comes back. When it returns, the next option is removing the bladder. FDA approval of a novel immunotherapy gives bladder cancer patients an alternative to surgical removal of the organ. The FDA has approved ImmunityBio’s therapy, Anktivo, for the treatment of non-muscle invasive bladder cancer (NMIBC), which is cancer found only on the inner layer of the bladder wall. The regulatory decision announced late Monday covers adults whose disease is unresponsive to Bacillus Calmette-Guérin (BCG), a standard of care immunotherapy for bladder cancer. BCG is a benign type of bacteria. Delivered to the bladder via a catheter, the bacteria induce an immune ...
ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The novel immunotherapy works by sparking activity from three types of immune cells. By Frank Vinluan Immunotherapy is already a treatment option for bladder cancer, but in many cases, these therapies fail or the cancer comes back. When it returns, the next option is removing the bladder. FDA approval of a novel immunotherapy gives bladder cancer patients an alternative to surgical removal of the organ. The FDA has approved ImmunityBio’s therapy, Anktivo, for the treatment of non-muscle invasive bladder cancer (NMIBC), which is cancer found only on the inner layer of the bladder wall. The regulatory decision announced late Monday covers adults whose disease is unresponsive to Bacillus Calmette-Guérin (BCG), a standard of care immunotherapy for bladder cancer. BCG is a benign type of bacteria. Delivered to the bladder via a catheter, the bacteria induce ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.